What we do Krebs Biochemicals & Industries Ltd manufactures active pharmaceutical ingredients using fermentation, serving global pharmaceutical and biotech markets with contract manufacturing and innovative biotech processes. |
Founded in 1,991 |
Market share Niche player with expertise in fermentation-based APIs, serving multinational pharma companies globally with specialized contract manufacturing capabilities. |
Problem solved Addresses the need for efficient, biotech-based pharmaceutical ingredient production through fermentation, reducing reliance on conventional chemical synthesis. |
Top clients or who we serve Serves large pharmaceutical companies and multinationals, primarily B2B, focusing on APIs and intermediates for global markets. |
Key management - |
Our journey and innovations Started in 1991, expanded capacity from 60 to 150 TPA, pioneered fermentation-based Vitamin C, commissioned cogeneration power plant, evolved product portfolio including phenylephrine and Simvastatin. |
Where we operate Primarily India with exports to global pharmaceutical markets; manufacturing units in Vizag and Nellore, India. |
Top products or what we offer Active pharmaceutical ingredients including Vitamin C (fermentation grade), Simvastatin, Phenylephrine HCl, Serratiopeptidase, and related drug intermediates. |
Top brands - |
Raw materials needed Fermentation substrates, chemical precursors for API synthesis. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely cyclical, linked to contract manufacturing orders and product approvals. |
Our industry position Specialist niche player in fermentation-based APIs; faces operational challenges but recognized for high-quality biotech processes. |
Financial highlights FY25 revenue around Rs. 43.3 Cr with net loss of Rs. 26.9 Cr due to operational shutdowns; undergoing turnaround efforts. |
Geographical revenue split Majority revenue from India with exports; specific split not disclosed. |
Order book - |
Whats driving growth Focus on product scale-up, new biotechnology-driven API development, strategic partnership with Ipca Laboratories, and regulatory compliance enhancements. |
Our future plans Revoking Vizag plant closure, product diversification, capacity utilization improvement, and financial restructuring for sustainable growth. |
Our green promise - |
Our people and values Emphasizes quality, safety, regulatory compliance, employee training in CGMP practices, and ethical manufacturing standards. |
Key challenges ahead Vizag plant closure by pollution board, financial losses, capacity underutilization, and need to optimize operations for viability. |
Interesting facts One of the few global companies producing APIs via fermentation; early adopter of biotechnology in Indian pharma manufacturing. |
Risks and strategy Risks include regulatory shutdowns and financial stress; strategy involves operational revival, product innovation, and leveraging promoter support. |
